Seropositivity – Page 14 – Communicable Diseases Research

RT-PCR negative COVID-19

RT-PCR 음성 코비드 -19

Research

Published on 2022-02-132022-09-01
Journal: BMC Infectious Diseases [Category] COVID19(2023년), Fulltext, SARS, 진단,

A Cross-Sectional Study of Exposure Factors Associated with Seropositivity for SARS-CoV-2 Antibodies during the Second Epidemic Wave among a Sample of the University of Corsica (France)

프랑스 코르시카 대학교 표본 중 2차 유행병 기간 동안 SARS-CoV-2 항체에 대한 혈청 양성과 관련된 노출 인자에 대한 단면 연구

Article

Published on 2022-02-102022-09-12
Journal: International Journal of Environmental Research an [Category] COVID19(2023년), MERS, SARS, 진단,

[키워드] 95% confidence interval Acute respiratory infection acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 anti-SARS-CoV-2 IgG antibodies Blood blood sampling conducted Contact contact with Coronavirus-2 Corsica cross-sectional survey ELISA exposure Factor France house individual Infection Loss of Smell neutralization test participant Population positive Prevention and control questionnaire respiratory infection Sample SARS-CoV-2 second second wave sera seroneutralization Seropositivity Seropositivity for SARS-CoV-2 Seroprevalence severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 Symptom tested the epidemic university virus neutralization test VNT Wave
[DOI] 10.3390/ijerph19041953 PMC 바로가기 [Article Type] Article

Seroprevalence of SARS-CoV-2 antibodies in social housing areas in Denmark

덴마크의 사회 주택 지역에서 SARS-COV-2 항체의 혈청 유병률

Research Article

Published on 2022-02-102022-09-01
Journal: BMC Infectious Diseases [Category] COVID19(2023년), Fulltext, MERS, SARS, 진단,

[키워드] 95% CI age antibodies Antibody test blood donor Blood donors can be used close contact concerning conducted Contact contact with COVID-19 COVID-19 pandemic Denmark ELISA assay female higher risk household Households IgG antibody increase in individual infected individuals Infection male National offered Older participant Participants point-of-care Population Prevalence prevalent preventive measure preventive measures questionnaire recommendations recruitment reported Result risk factor Risk factors risk ratio risk ratios SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-CoV-2 IgM SARS-CoV-2 seroprevalence selected seropositive Seropositivity Seroprevalence significantly higher significantly increased Social housing areas socioeconomic status supplementary material thought total Ig with COVID-19
[DOI] 10.1186/s12879-022-07102-1 PMC 바로가기 [Article Type] Research Article

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

브라질에서 코로나 박 코비드 -19 백신의 이전 수용자 (RHH-001)의 이전 수용자에서 이종과 동종 코비드 -19 부스터 백신 접종

Clinical Trial

Published on 2022-02-052022-08-13
Journal: Lancet (London, England) [Category] COVID19(2023년), MERS, SARS, 변종, 유전자 메커니즘, 임상, 진단, 치료기술,

[키워드] 95% CI Ad26 Ad26.COV2-S Ad26.COV2-S vaccine Administered administration adverse events age All participant All participants anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody anti-spike IgG response Anti-spike IgG responses Antibody concentrations assigned AstraZeneca AZD1222 B.1.1.529 B.1.617.2 baseline binding blind BNT162b2 boost booster booster dose booster vaccination Booster vaccine Brazil ChAdOx1 ChAdOx1 nCoV-19 ChAdOx1 nCoV-19 vaccine Concentration CoronaVac COVID-19 COVID-19 vaccine detectable discharged home dose eligible ENhance except for finding FIVE for inclusion four groups funding geometric geometric mean geometric mean ratio geometric mean ratios group Heterologous homologous homologous booster responses IgG antibody IgG responses immune response immune responses immunogenicity IMPROVE inactivated Infection inferiority janssen Live virus neutralising antibodies Local local and systemic reactogenicity profiles Ministry of Health mRNA vaccine Neutralising Antibodies neutralising antibody neutralising antibody titre neutralising antibody titres non-inferiority non-inferiority margin Older Older adults Omicron variant Omicron variants outcome participant Pfizer Pfizer–BioNTech phase 4 primary analysis Primary outcome profiles pseudovirus neutralising antibodies randomisation randomised Randomly reached recipient recombinant adenoviral vectored vaccine recombinant adenoviral-vectored ChAdOx1 nCoV-19 vaccine regimen Registered RHH-001 robust secondary Secondary outcomes Serious Adverse Events Seropositivity significant increase Sinovac stratified systemic reactogenicity the vaccine Vaccine vectored vaccine virus neutralising antibody whole-virion SARS-CoV-2 vaccine
[DOI] 10.1016/S0140-6736(22)00094-0 PMC 바로가기 [Article Type] Clinical Trial

Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis

다발성 경화증을 가진 회복기 COVID-19 환자의 SARS-CoV-2에 대한 체액 및 세포 반응

Article

Published on 2022-02-012022-09-11
Journal: Neurology® neuroimmunology & neuroinflammation [Category] MERS, 바이오마커, 진단, 치료법,

[키워드] absence acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis anti-CD20 anti-CD20 therapy anti-CD20 treatment antibodies antibody Antibody testing Antibody titer Antibody titers cellular cellular response Characteristics convalescent coronavirus COVID-19 decrease demographics examined Factor humoral Humoral and cellular responses Humoral response IFN-γ Immunoglobulin Immunoglobulin G Interferon-gamma likelihood male Multiple multiple sclerosis Multivariate analysis not differ Nucleocapsid proteins Patient patients persistence producing progressive disease respiratory response Retrospective study SARS-CoV-2 SARS-CoV-2 antibody testing sclerosis seronegative patient seropositive Seropositivity severe acute respiratory syndrome Coronavirus severe COVID-19 therapy
[DOI] 10.1212/NXI.0000000000001143 PMC 바로가기 [Article Type] Article

Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient

Article

Published on 2022-02-012022-11-15
Journal: The Journal of Infectious Diseases [Category] COVID19(2023년), SARS, 진단,

[키워드] acute respiratory syndrome anti-SARS-CoV-2 antibody caused CD4 T-cell cellular coronavirus coronavirus 2 coronavirus disease COVID-19 deficiency development Diagnosis Evidence Factor Genetic hospital Hospitalized humoral Humoral response immune escape mutations immune profiling Immunocompromised Immunocompromised patients Infection initial Lineage longitudinal male memory response neutralization titer Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing titer Patient performed Phylogenetic analysis Primary infection Profiling recipient reduction in Reinfection renal required respiratory SARS-CoV-2 SARS-COV-2 infection secondary infections Seropositivity Solid threshold Transplant Viral genome sequencing virus with COVID-19
[DOI] 10.1093/infdis/jiab553 PMC 바로가기

Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study

인도 의료 종사자들 사이에서 ChAdOx1-nCOV(Covishield™) 및 BBV-152(Covaxin™) 백신을 사용한 체액 항체 동역학: 6개월 종단면 코로나바이러스 백신 유도 항체 역가(COVAT) 연구

Article

Published on 2022-02-012022-09-12
Journal: Diabetes & metabolic syndrome [Category] COVID19(2023년), MERS, SARS, 진단,

Spike-based COVID-19 immunization increases antibodies to nucleocapsid antigen

스파이크 기반 COVID-19 면역은 뉴클레오캡시드 항원에 대한 항체를 증가시킵니다

Article

Published on 2022-02-012022-09-11
Journal: Translational research : the journal of laboratory [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술, 치료법,

Assessing the performance of a serological point-of-care test in measuring detectable antibodies against SARS-CoV-2

SARS-COV-2에 대한 검출 가능한 항체를 측정 할 때 혈청 학점 테스트의 성능 평가

Research Article

Published on 2022-01-312022-09-10
Journal: PLoS ONE [Category] 진단, 치료기술,

Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial

보조제 서브유닛 단백질 COVID-19 백신, SCB-2019의 효능: 2상 및 3상 다기관, 이중 맹검, 무작위 배정, 위약 대조 시험

Clinical Trial

Published on 2022-01-292022-09-11
Journal: Lancet (London, England) [Category] 변종, 임상,

[키워드] 1:1 95% CI alum assigned baseline Belgium biopharmaceutical Brazil caused chloride circulating Clover Coalition country COVID 19 COVID-19 COVID-19 case COVID-19 vaccine CpG Cutoff dose doses double-blind effective vaccine Effective vaccines Efficacy efficacy analysis elicited Endpoint enrolled EudraCT exclusion FIVE follow-up period groups Health health condition injection injection site pain intramuscular dose Local median Mild-to-moderate moderate-to-severe COVID-19 MOST multicentre notable Older pandemic participant per-protocol per-protocol population Phase 2 Placebo placebo recipients placebo-controlled trial predominant primary endpoints Protein provide randomisation randomised Randomly receive Registered RT-PCR Safe SAR-CoV-2 SARS CoV SARS-CoV-2 SCB-2019 second dose seronegative participant Seropositivity severe COVID-19 severity Sodium chloride South Africa subset subunit systemic adverse event systemic adverse events Vaccine vaccine efficacy vaccinee vaccinees variant virus virus variants viruses was done
[DOI] 10.1016/S0140-6736(22)00055-1 PMC 바로가기 [Article Type] Clinical Trial